CenterBook Partners LP Takes Position in Progyny, Inc. (NASDAQ:PGNY)

CenterBook Partners LP bought a new stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 92,369 shares of the company's stock, valued at approximately $1,593,000. CenterBook Partners LP owned 0.11% of Progyny as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Signaturefd LLC boosted its stake in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares during the last quarter. GAMMA Investing LLC grew its holdings in Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares during the last quarter. Caitlin John LLC lifted its position in shares of Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after purchasing an additional 3,183 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of Progyny during the fourth quarter worth about $74,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Bank of America upped their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research report on Monday, March 31st. Finally, Canaccord Genuity Group boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, February 28th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $23.64.

Remove Ads

Progyny Trading Down 1.2 %

PGNY traded down $0.27 during trading hours on Tuesday, hitting $21.81. The company's stock had a trading volume of 1,077,203 shares, compared to its average volume of 1,729,231. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $34.40. The firm has a market capitalization of $1.86 billion, a PE ratio of 37.60, a PEG ratio of 2.39 and a beta of 1.33. The company has a 50-day simple moving average of $21.99 and a 200 day simple moving average of $18.74.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.